Radnor Capital Management LLC Buys 2,400 Shares of Edwards Lifesciences Co. (NYSE:EW)

Radnor Capital Management LLC boosted its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 11.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 24,070 shares of the medical research company’s stock after acquiring an additional 2,400 shares during the quarter. Radnor Capital Management LLC’s holdings in Edwards Lifesciences were worth $1,745,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. Ehrlich Financial Group increased its stake in Edwards Lifesciences by 5.7% during the first quarter. Ehrlich Financial Group now owns 10,950 shares of the medical research company’s stock worth $794,000 after acquiring an additional 586 shares during the last quarter. Unique Wealth LLC bought a new stake in Edwards Lifesciences during the first quarter worth approximately $248,000. Retireful LLC bought a new stake in Edwards Lifesciences during the first quarter worth approximately $387,000. Orser Capital Management LLC bought a new stake in Edwards Lifesciences during the first quarter worth approximately $2,101,000. Finally, Merit Financial Group LLC increased its stake in Edwards Lifesciences by 93.4% during the first quarter. Merit Financial Group LLC now owns 10,793 shares of the medical research company’s stock worth $782,000 after acquiring an additional 5,212 shares during the last quarter. 79.46% of the stock is owned by institutional investors.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, CEO Bernard J. Zovighian sold 6,164 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $69.51, for a total transaction of $428,459.64. Following the sale, the chief executive officer now owns 59,083 shares of the company’s stock, valued at approximately $4,106,859.33. This trade represents a 9.45% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 400 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $69.48, for a total value of $27,792.00. Following the sale, the vice president now directly owns 22,588 shares in the company, valued at $1,569,414.24. This trade represents a 1.74% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 59,012 shares of company stock valued at $4,224,717. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Stock Down 0.3%

Shares of NYSE EW opened at $77.56 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm has a market capitalization of $45.50 billion, a price-to-earnings ratio of 11.13, a PEG ratio of 4.82 and a beta of 1.12. The stock has a 50 day moving average price of $73.98 and a 200 day moving average price of $72.75. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $95.25.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.60 by $0.04. The firm had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.40 billion. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Edwards Lifesciences’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.66 earnings per share. Sell-side analysts expect that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on EW. Royal Bank of Canada reissued an “outperform” rating and set a $85.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Citigroup reissued a “buy” rating and set a $95.00 price objective (up from $84.00) on shares of Edwards Lifesciences in a research note on Thursday, May 22nd. Wolfe Research cut Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 12th. Robert W. Baird upped their target price on Edwards Lifesciences from $72.00 to $75.00 and gave the company a “neutral” rating in a research note on Thursday, April 24th. Finally, Piper Sandler upped their target price on Edwards Lifesciences from $80.00 to $83.00 and gave the company an “overweight” rating in a research note on Tuesday, May 13th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, Edwards Lifesciences has a consensus rating of “Hold” and a consensus target price of $80.20.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.